Drug Trial Radar · NCT04446104
A Preventive Treatment for Migrant Workers at High-risk of COVID-19
Last checked: Nov 19, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,257
Actual
Start
May 13, 2020
Primary completion
Aug 31, 2020
Study completion Aug 31, 2020
Sponsor
- Lead sponsor
- National University Hospital, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Male only, from 21 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In December 2019, a novel coronavirus, now called COVID-19, emerged as a global health threat from Wuhan, China. Within weeks, the contagious virus spread within and between communities, causing a lower respiratory tract infection dominated by symptoms of fever, cough and sore throat. The incubation period was estimated at between 5 to 7 days, but could last as long as 14 days. Although COVID-19 causes a mostly mild and self-limiting disease, respiratory involvement has been reported in about 5% of the population, requiring supplemental oxygen and even ventilatory support to relieve hypoxia. Alveolar damage, fibrosis and consolidation have been reported in radiologic and post-mortem studies. Existing data suggest a mortality rate of COVID-19 is approximately 1-2%, higher among individuals with pre-existing comorbidities and in healthcare systems with suboptimal access to ventilatory support. Given its high transmissibility, COVID-19 has quickly spread across the globe within a short interval. By 27 April 2020, over 3 million people around the world have been diagnosed with COVID-19, and more 200,000 have succumbed to the disease. As a proportion of patients manifest mild or no symptoms, these numbers are likely an underestimate of the actual number of patients with COVID-19. More disconcertingly, patients are known to shed viruses despite mild or no symptoms, making it essential that a collective approach against COVID-19 incorporate active pharmacological treatment to prevent or mitigate virus pathogenesis prior to its potential evolution to cause respiratory distress. To date, clinical trials have focused on the treatment of hospitalised patients diagnosed with COVID-19; only few have examined the clinical benefits of pharmacological agents despite few compelling in vitro data. The relatively high transmission of COVID-19 in a closed dormitory environment of migrant workers in Singapore presents a real-life scenario where a prophylaxis treatment could reduce the impact of the disease. In Singapore, there are well grounded concerns an excess in cases could pose the possibility of strain in healthcare system and mentally drain her workers. The availability of an effective prophylaxis treatment is highly desirable to potentially reduce this burden. Data from the current study could also have implications on how future outbreaks in high-density areas should be managed, especially when residents are subjected to quarantine and isolation.
Conditions
- Covid-19
Interventions
Hydroxychloroquine Sulfate TabletsDrug
Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
Ivermectin 3mg TabDrug
Ivermectin tablet 12mg single dose
ZincDrug
Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
Povidone-IodineDrug
Povidone-iodine throat spray (3 times daily) for 42 days
Vitamin CDietary supplement
Vitamin C tablet 500mg daily for 42 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)Time frame: At the end of study dosing, which is day 42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tuas South Dormitory
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.